Principles of opioid use in cancer pain

Journal of Clinical Oncology

Volumn 32, Issue 16, 2014, Pages 1662-1670

  Portenoy, Russell K ^a   Ahmed, Ebtesam ^a  

^a BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 METHYLNALTREXONE; ALVIMOPAN; BUPRENORPHINE; BUTORPHANOL; CODEINE; FENTANYL; HYDROCODONE; HYDROMORPHONE; LEVORPHANOL; METHADONE; MORPHINE; MU OPIATE RECEPTOR AGONIST; NALBUPHINE; NALOXONE; NALTREXONE; OPIATE; OXYCODONE; OXYMORPHONE; PENTAZOCINE; PETHIDINE; TAPENTADOL; TRAMADOL;

BREAKTHROUGH PAIN; CANCER PAIN; CONSTIPATION; DRUG ADMINISTRATION ROUTE; DRUG CROSS TOLERANCE; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG USE; HUMAN; HYPERALGESIA; INDIVIDUALIZATION; LONG TERM CARE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK MANAGEMENT; SOMNOLENCE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANALGESICS, OPIOID; DRUG ADMINISTRATION ROUTES; HUMANS; NEOPLASMS; PAIN; PAIN MANAGEMENT;

EID: 84905844127     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.52.5188     Document Type: Review

References (58)

1. Goudas LC, Bloch R, Gialeli-Goudas M: The epidemiology of cancer pain. Cancer Invest 23:182-190, 2005 (Pubitemid 40463916)
2. Caraceni A, Hanks G, Kaasa S, et al: Use of opioid analgesics in the treatment of cancer pain: Evidence-based recommendations from the EAPC. Lancet Oncol 13:e58-e68, 2012
3. Dy SM, Asch SM, Naeim A, et al: Evidence-based standards for cancer pain management. J Clin Oncol 26:3879-3885, 2008
4. Koyyalagunta D, Bruera E, Solanki DR, et al: A systematic review of randomized trials on the effectiveness of opioids for cancer pain. Pain Physician 15:ES39-ES58, 2012
5. World Health Organization: Cancer Pain Relief. Geneva, Switzerland, World Health Organization, Office of Publications, 1986
6. Deandrea S, Montanari M, Moja L, et al: Prevalence of undertreatment in cancer pain: A review of published literature. Ann Oncol 19:1985-1991, 2008
7. Breuer B, Fleishman SB, Cruciani RA, et al: Medical oncologists' attitudes and practice in cancer pain management: A national survey. J Clin Oncol 29:4769-4775, 2011
8. Portenoy RK: Treatment of cancer pain. Lancet 377:2236-2247, 2011
9. Pasternak GW: Opioids and their receptors: Are we there yet? Neuropharmacology [epub ahead of print on April 26, 2013]
10. Lötsch J, Rohrbacher M, Schmidt H, et al: Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation? Pain 144:119-124, 2009
11. Quigley C, Joel S, Patel N, et al: Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related pain. Palliat Med 17:185-190, 2003 (Pubitemid 36432596)
12. Dean M: Opioids in renal failure and dialysis patients. J Pain Symptom Manage 28:497-504, 2004
13. Ahmedzai S, Brooks D: Transdermal fentanyl versus sustained-release oral morphine in cancer pain: Preference, efficacy, and quality of life - The TTS-Fentanyl Comparative Trial Group. J Pain Symptom Manage 13:254-261, 1997 (Pubitemid 27240678)
14. Tassinari D, Sartori S, Tamburini E, et al: Transdermal fentanyl as a front-line approach to moderate-severe pain: A meta-analysis of randomized clinical trials. J Palliat Care 25:172-180, 2009
15. Tassinari D, Drudi F, Rosati M, et al: Transdermal opioids as front line treatment of moderate to severe cancer pain: A systemic review. Palliat Med 25:478-487, 2011
16. Eap CB, Buclin T, Baumann P: Interindividual variability of the clinical pharmacokinetics of methadone: Implications for the treatment of opioid dependence. Clin Pharmacokinet 41:1153-1193, 2002 (Pubitemid 35398691)
17. Weschules DJ, Bain KT: A systematic review of opioid conversion ratios used with methadone for the treatment of pain. Pain Med 9:595-612, 2008
18. Cruciani RA, Sekine R, Homel P, et al: Measurement of QTc in patients receiving chronic methadone therapy. J Pain Symptom Manage 29:385-391, 2005 (Pubitemid 40602519)
19. Kapur BM, Hutson JR, Chibber T, et al: Methadone: A review of drug-drug and pathophysiological interactions. Crit Rev Clin Lab Sci 48:171-195, 2011
20. Mercadante S, Porzio G, Ferrera P, et al: Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: A 4-week, nonrandomized, open-label, uncontrolled observational study. Clin Ther 31:2134-2138, 2009
21. Apolone G, Corli O, Negri E, et al: Effects of transdermal buprenorphine on patients-reported outcomes in cancer patients: Results from the Cancer Pain Outcome Research (CPOR) Study Group. Clin J Pain 25:671-682, 2009
22. Poulain P, Denier W, Douma J, et al: Efficacy and safety of transdermal buprenorphine: A randomized, placebo-controlled trial in 289 patients with severe cancer pain. J Pain Symptom Manage 36:117-125, 2008 (Pubitemid 352010492)
23. Davis MP: Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. J Support Oncol 10:209-219, 2012
24. Wedam EF, Bigelow GE, Johnson RE, et al: QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med 167:2469-2475, 2007 (Pubitemid 350254906)
25. Wilder-Smith CH, Schimke J, Osterwalder B, et al: Oral tramadol, a mu-opioid agonist and monoamine reuptake-blocker, and morphine for strong cancer-related pain. Ann Oncol 5:141-146, 1994
26. Leppert W: Tramadol as an analgesic for mild to moderate cancer pain. Pharmacol Rep 61:978-992, 2009
27. Mercadante S, Porzio G, Aielli F, et al: Opioid switching from and to tapentadol extended release in cancer patients: Conversion ratio with other opioids. Curr Med Res Opin 29:661-666, 2013
28. Ripamonti CI, Bareggi C: Pharmacology of opioid analgesia: Clinical principles, in Bruera EB, Portenoy RK (eds): Cancer Pain: Assessment and Management. New York, NY, Cambridge University Press, 2010 pp. 195-229
29. Mercadante S, Villari P, Ferrera P, et al: Optimization of opioid therapy for preventing incident pain associated with bone metastases. J Pain Symptom Manage 28:505-510, 2004 (Pubitemid 39422489)
30. Walsh D, Tropiano PS: Long-term rectal administration of high-dose sustained-release morphine tablets. Support Care Cancer 10:653-655, 2002 (Pubitemid 36056265)
31. Wilcock A, Jacob JK, Charlesworth S, et al: Drugs given by a syringe driver: A prospective multicentre survey of palliative care services in the UK. Palliat Med 20:661-664, 2006 (Pubitemid 44782498)
32. Thomas JR, Wallace MS, Yocum RC, et al: The INFUSE-Morphine study: Use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneously administered morphine in patients with advanced illness. J Pain Symptom Manage 38:663-672, 2009
33. Thomas JR, Yocum RC, Haller MF, et al: The INFUSE-Morphine IIB study: Use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneous morphine in healthy volunteers. J Pain Symptom Manage 38:673-682, 2009
34. Mace SE, Harb G, Friend K, et al: Cost-effectiveness of recombinant human hyaluronidase-facilitated subcutaneous versus intravenous rehydration in children with mild to moderate dehydration. Am J Emerg Med 31:928-934, 2013
35. Mercadante S, Portenoy RK: Opioid poorly-responsive cancer pain: Part 3. Clinical strategies to improve opioid responsiveness. J Pain Symptom Manage 21:338-354, 2001 (Pubitemid 32331888)
36. Reddy A, Yennurajalingam S, Pulivarthi K, et al: Frequency, outcome, and predictors of success within 6 weeks of an opioid rotation among outpatients with cancer receiving strong opioids. Oncologist 18:212-220, 2013
37. Knotkova H, Fine PG, Portenoy RK: Opioid rotation: The science and limitations of the equianalgesic dose table. J Pain Symptom Manage 38:426-439, 2009
38. Fine PG, Portenoy RK, Ad Hoc Expert Panel on Evidence Review and Guidelines for Opioid Rotation: Establishing "best practices" for opioid rotation: Conclusions of an expert panel. J Pain Symptom Manage 38:418-425, 2009
39. Davies A, Buchanan A, Zeppetella G, et al: Breakthrough cancer pain: An observational study of 1000 European oncology patients. J Pain Symptom Manage 46:619-628, 2013
40. Deandrea S, Corli O, Consonni D, et al: Prevalence of breakthrough cancer pain: A systematic review and a pooled analysis of published literature. J Pain Symptom Manage [epub ahead of print on June 21, 2013]
41. Portenoy RK, Bruns D, Shoemaker B, et al: Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, part 2: Impact on function, mood, and quality of life. J Opioid Manag 6:109-116, 2010
42. Caraceni A, Davies A, Poulain P, et al: Guidelines for the management of breakthrough pain in patients with cancer. J Natl Compr Canc Netw 11:S29-S36, 2013
43. Davies AN, Dickman A, Reid C, et al: The management of cancer-related breakthrough pain: Recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain 13:331-338, 2009
44. Zeppetella G: Evidence-based treatment of cancer-related breakthrough pain with opioids. J Natl Compr Canc Netw 11:S37-S43, 2013
45. Jandhyala R, Fullarton JR, Bennett MI: Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: A meta-analysis of comparative trials. J Pain Symptom Manage 46:573-580, 2013
46. Holzer P, Ahmedzai SH, Niederle N, et al: Opioid-induced bowel dysfunction in cancer-related pain: Causes, consequences, and a novel approach for its management. J Opioid Manag 5:145-151, 2009
47. Becker G, Galandi D, Blum HE: Peripherally acting opioid antagonists in the treatment of opiate-related constipation: A systematic review. J Pain Symptom Manage 34:547-565, 2007 (Pubitemid 350001379)
48. Ford AC, Brenner DM, Schoenfeld PS: Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: Systematic review and meta-analysis. Am J Gastroenterol 108:1566-1574, 2013
49. Stone P, Minton O: European Palliative Care Research collaborative pain guidelines: Central sideeffects management - What is the evidence to support best practice in the management of sedation, cognitive impairment and myoclonus? Palliat Med 25:431-441, 2011
50. Walker JM, Farney RJ, Rhondeau SM, et al: Chronic opioid use is a risk factor for the development of central sleep apnea and ataxic breathing. J Clin Sleep Med 3:455-461, 2007 (Pubitemid 47378247)
51. Rhodin A, Stridsberg M, Gordh T: Opioid endocrinopathy: A clinical problem in patients with chronic pain and long-term oral opioid treatment. Clin J Pain 26:374-380, 2010
52. Chu LF, Angst MS, Clark D: Opioid-induced hyperalgesia in humans: Molecular mechanisms and clinical considerations. Clin J Pain 24:479-496, 2008
53. Bannister K, Dickenson AH: Opioid hyperalgesia. Curr Opin Support Palliat Care 4:1-5, 2010
54. Katz NP, Adams EH, Benneyan JC, et al: Foundations of opioid risk management. Clin J Pain 23:103-118, 2007 (Pubitemid 46145457)
55. Kuehn BM: Opioid prescriptions soar: Increase in legitimate use as well as abuse. JAMA 297:249-251, 2007
56. Extended-Release (ER) and Long-Acting (LA) Opioid Analgesics Risk Evaluation and Mitigation Strategy (REMS). http://www.fda.gov/downloads/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM311290.pdf
57. Savage SR, Joranson DE, Covington EC, et al: Definitions related to the medical use of opioids: Evolution towards universal agreement. J Pain Symptom Manage 26:655-667, 2003 (Pubitemid 36802289)
58. Portenoy RK: Acute and chronic pain, in Ruiz P, Strain E (eds): Lowinson and Ruiz's Substance Abuse: A Comprehensive Textbook (ed 5). Philadelphia, PA, Lippincott, Williams & Wilkins, 2011, pp 695-720